Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

6 Jan 2006

Abstract excerpt

Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found previously to be strongly associated with clinical outcome. In this study we aimed to develop an algorithm based on expression of GCB/ABC-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to Lymphoma Diagnosis and Treatment
Share to T-cell and Retrovirus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16400625
DOI: 10.1002/path.1924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemical profiling based on Bcl‐2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphomaPMID 16400625Read ↗

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.Semantic proximity Read ↗

<i>BCL2</i> Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Prediction of Overall Survival Status of Diffuse Large B-Cell Lymphoma Using a Prognostic Classification ModelSemantic proximity Read ↗

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.Semantic proximity Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read ↗

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximabSemantic proximity Read ↗

Microarray‐based classification of diffuse large B‐cell lymphomaSemantic proximity Read ↗

[Characteristics and survival analysis of 60 cases of primary diffuse large B-cell lymphoma of the breast].Semantic proximity Read ↗

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype.Semantic proximity Read ↗

Improved Personalized Survival Prediction of Patients With Diffuse Large B-cell Lymphoma Using Gene Expression ProfilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.